The Benchmark Company initiated coverage on Reviva Pharmaceuticals with a new price target
$RVPH
Biotechnology: Pharmaceutical Preparations
Health Care
The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00